FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome
Michael Schieber(Northwestern University), John D. Crispino(St. Jude Children's Research Hospital)
Cited by 33
Related Papers
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3
|Journal of Clinical Investigation|2021|88
DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3
|The Journal of Experimental Medicine|2015|84
Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis
|Blood|2019|50
<i>Gata1s</i> mutant mice display persistent defects in the erythroid lineage
|Blood Advances|2022|9
FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome
|Journal of Clinical Investigation|2026|0